Fig. S5.

Anti-mouse CD47 nanobody A4 does not influence human macrophage phagocytosis of human tumor cells. (A) Human monocyte-derived macrophage-mediated ADCP of Raji^GFP tumor cells treated with 2 μg/mL anti-human CD20 mAb (Rituximab) and increasing concentrations of CV1 (anti-human CD47) or A4 (anti-mouse CD47). The data shown are the mean (n = 3), and error bars indicate SD. Phagocytosis is quantified as the percentage of CD33-positive macrophages that have engulfed GFP-positive Raji cells as depicted in the representative FACS plots (B) and normalized to the maximal observed response. The dashed lines represent data fit to a one-site LogEC₅₀ model in Prism.